Difficult diagnosis of multiple myeloma with acute renal failure as first clinical manifestation
Abstract
About the Authors
E. O. SherbakovaRussian Federation
E. I. Prokopenko
Russian Federation
A. V. Vatazin
Russian Federation
E. V. Kataeva
Russian Federation
R. V. Koshelev
Russian Federation
S. U. Gulimova
Russian Federation
N. M. Fominykh
Russian Federation
References
1. Бессмельцев С.С., Абдулкдыров К.М. Множественная миелома. СПб.: Диалект 2004; 448 с.
2. Бирюкова Л.С., Тангиева Л.М., Тимохов В.С. и соавт. Комплексная терапия хронической почечной недостаточности у больных миеломной болезнью. Нефрология и диализ 2002; 4 (2): 98-105.
3. Голенков А.К., Шабалин В.Н. Множественная миелома. СПб.: Гиппократ 1995; 144 с.
4. Гордовская Н.Б. Поражение почек при множественной миеломе. Клиническая медицина 1995; 3: 71-77.
5. Alexanian R., Haut A., Kahn A.U. et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969; 208: 1680-1685.
6. Alexanian R., Barlogie B., Dixon D. Renal failure in multiple myeloma: pathogenesis and prognostic factors. Arch Intern Med 1990; 150: 1693-1695.
7. Bensinger W.I., Rowley S.D., Demirer T. et al. High dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. J Clin Oncol 1996; 14: 1447-1456.
8. Blade J., Kyle R.A., Greipp P.R. et al. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol 1996; 93: 345-351.
9. Child J.A., Morgan G.J., Davies F.E. et al. High dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
10. Clark A.D., Shetty A., Soutar R. Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Reviews 1999; 13: 79-90.
11. Haubitz M., Peest D. Myeloma - new approaches to combined nephrological-hematological management. Nephrol Dial Transplant 2006; 21: 582-590.
12. Jagannath S., Barlogie B., Berenson J.R. et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer 2005; 103: 1195-1200.
13. Kyle R.A., Gertz M.A., Witzing T.E. et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21-23.
14. Maack T., Johnson V., Kau S.T. et al. Renal filtration, transport and metabolism of low-molecular-weight proteins: a review. Kidney Int 1979; 16: 251-270.
15. Myeloma Trialists¢ Collaborative group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6, 6633 patients from 27 randomized trials. J Clin Oncol 1998; 16: 3832-3842.
16. Richardson P.G., Barlogie B., Berenson J. et al. A phase 2 study of Bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
17. Singhal S., Mehta J., Desikan R. et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
18. Solomon A., Weiss D.T., Kattine A.A. Nephrotoxic potential of Bence Jones proteins. N Engl J Med 1991; 324: 1485-1851.
Review
For citations:
Sherbakova E.O., Prokopenko E.I., Vatazin A.V., Kataeva E.V., Koshelev R.V., Gulimova S.U., Fominykh N.M. Difficult diagnosis of multiple myeloma with acute renal failure as first clinical manifestation. Nephrology and Dialysis. 2006;8(4):370-374. (In Russ.)